CDK12-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade.

Michael T. Schweizer,Roman Gulati,Landon Carter Brown,Rana R. McKay,Tanya B. Dorff,Deepak Kilari,Pankaj Vats,Vaibhav G. Patel,William Oh,Andrew J. Armstrong,Robert B. Montgomery,Ajjai Alva

CDK12-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade.

2020

Michael T. Schweizer
Roman Gulati
Landon Carter Brown
Rana R. McKay
Tanya B. Dorff
Deepak Kilari
Pankaj Vats
Vaibhav G. Patel
William Oh
Andrew J. Armstrong
Robert B. Montgomery
Ajjai Alva

191Background: Translational studies have shown that CDK12 mutations may delineate an immunoresponsive subgroup of PC, characterized by high neoantigen burden. Given that these mutations may define...

Keywords:

CDK12
Blockade
Cancer research
Prostate cancer
Immune checkpoint
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations